keyword
MENU ▼
Read by QxMD icon Read
search

Cost cancer

keyword
https://www.readbyqxmd.com/read/28813112/what-do-cochrane-systematic-reviews-say-about-the-clinical-effectiveness-of-screening-and-diagnostic-tests-for-cancer
#1
André Tito Pereira Bueno, Vladimir Lisboa Capelasso, Rafael Leite Pacheco, Carolina de Oliveira Cruz Latorraca, Tiago Biachi de Castria, Daniela Vianna Pachito, Rachel Riera
CONTEXT AND OBJECTIVE: The purpose of screening tests for cancer is to detect it at an early stage in order to increase the chances of treatment. However, their unrestrained use may lead to unnecessary examinations, overdiagnosis and higher costs. It is thus necessary to evaluate their clinical effects in terms of benefits and harm. DESIGN AND SETTING: Review of Cochrane systematic reviews, carried out in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo...
July 2017: São Paulo Medical Journal, Revista Paulista de Medicina
https://www.readbyqxmd.com/read/28811705/colorectal-cancer-screening-an-updated-review-of-the-available-options
#2
REVIEW
Iyad A Issa, Malak Noureddine
Colorectal cancer (CRC) is a significant cause of morbidity and mortality worldwide. However, colon cancer incidence and mortality is declining over the past decade owing to adoption of effective screening programs. Nevertheless, in some parts of the world, CRC incidence and mortality remain on the rise, likely due to factors including "westernized" diet, lifestyle, and lack of health-care infrastructure and resources. Participation and adherence to different national screening programs remain obstacles limiting the achievement of screening goals...
July 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28809811/mutation-clusters-from-cancer-exome
#3
Zura Kakushadze, Willie Yu
We apply our statistically deterministic machine learning/clustering algorithm *K-means (recently developed in https://ssrn.com/abstract=2908286) to 10,656 published exome samples for 32 cancer types. A majority of cancer types exhibit a mutation clustering structure. Our results are in-sample stable. They are also out-of-sample stable when applied to 1389 published genome samples across 14 cancer types. In contrast, we find in- and out-of-sample instabilities in cancer signatures extracted from exome samples via nonnegative matrix factorization (NMF), a computationally-costly and non-deterministic method...
August 15, 2017: Genes
https://www.readbyqxmd.com/read/28809008/in-silico-design-of-anticancer-peptides
#4
Shailesh Kumar, Hui Li
In the past few years, small peptides having anticancer properties have emerged as a potential avenue for cancer therapy. Compared to current anti-cancer chemotherapeutic drugs (or small molecules), anticancer peptides (ACPs) have numerous advantageous properties, such as high specificity, low production cost, high tumor penetration, ease of synthesis and modification. However, in wet lab setups, identification and characterization of novel ACPs is a time-consuming and labor-intensive process. Therefore, in silico designing of anticancer peptides is beneficial, prior to their synthesis and characterization...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28808840/comparison-of-health-state-values-derived-from-patients-and-individuals-from-the-general-population
#5
Mihir Gandhi, Ru San Tan, Raymond Ng, Su Pin Choo, Whay Kuang Chia, Chee Keong Toh, Carolyn Lam, Phong Teck Lee, Nang Khaing Zar Latt, Kim Rand-Hendriksen, Yin Bun Cheung, Nan Luo
PURPOSE: Utility values are critical for cost-utility analyses that guide healthcare decisions. We aimed to compare the utility values of the 5-level EuroQoL-5Dimension (EQ-5D-5L) health states elicited from members of the general public and patients with heart disease or cancer. METHODS: In face-to-face interviews with 157 heart disease patients, 169 cancer patients, and 169 members from the general population, participants valued 10 EQ-5D-5L health states using a composite Time Trade-Off method...
August 14, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28808743/saving-costs-in-cancer-patient-management-through-molecular-imaging
#6
EDITORIAL
Carl von Gall, Piotr Maniawski, Fred Verzijlbergen, Ignasi Carrio, Thomas Beyer, Antonis Kalemis
No abstract text is available yet for this article.
August 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28807952/emerging-role-of-hpv-self-sampling-in-cervical-cancer-screening-for-hard-to-reach-women-focused-literature-review
#7
REVIEW
Tina R Madzima, Mandana Vahabi, Aisha Lofters
OBJECTIVE: To provide a focused critical review of the literature on the acceptability, feasibility, and uptake of human papillomavirus (HPV) self-sampling among hard-to-reach women. QUALITY OF EVIDENCE: A focused search to obtain relevant literature published in English between 1997 and 2015 was done using PubMed and EMBASE using search terms including HPV self-test or HPV self-sample or HPV kit in combination with acceptability or feasibility. Only studies that focused on never-screened or underscreened populations were included in this review...
August 2017: Canadian Family Physician Médecin de Famille Canadien
https://www.readbyqxmd.com/read/28807605/adjuvant-hpv-vaccination-for-anal-cancer-prevention-in-hiv-positive-men-who-have-sex-with-men-the-time-is-now
#8
Ashish A Deshmukh, Scott B Cantor, Elisabeth Fenwick, Elizabeth Y Chiao, Alan G Nyitray, Elizabeth A Stier, Stephen E Goldstone, Timothy Wilkin, Jagpreet Chhatwal
IMPORTANCE: Outcomes of treating high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, remain uncertain. Emerging evidence shows that post HSIL treatment adjuvant quadrivalent human papillomavirus (qHPV) vaccination improves the effectiveness of treatment. However, no recommendations exist regarding the use of qHPV vaccine as an adjuvant form of therapy. Our objective was to determine whether post-treatment adjuvant vaccination should be adopted in HIV-infected MSM (individuals at highest risk for anal cancer) on the basis of cost-effectiveness determined using existing evidence or whether future research is needed...
August 11, 2017: Vaccine
https://www.readbyqxmd.com/read/28807351/cost-effectiveness-of-nivolumab-in-advanced-renal-cell-carcinoma
#9
Michal Sarfaty, Moshe Leshno, Noa Gordon, Assaf Moore, Victoria Neiman, Eli Rosenbaum, Daniel A Goldstein
BACKGROUND: In recent years, new drugs have been introduced for second-line treatment of advanced renal cell carcinoma (RCC). Nivolumab increases overall survival and is associated with less toxicity compared to everolimus in this setting according to the CheckMate 025 study. However, because of the high cost of nivolumab, there is a need to define its value by considering both efficacy and cost. OBJECTIVE: To estimate the cost effectiveness of nivolumab for second-line treatment of advanced RCC from the US payer perspective...
August 11, 2017: European Urology
https://www.readbyqxmd.com/read/28807052/whole-blood-rna-transcript-based-models-can-predict-clinical-response-in-two-large-independent-clinical-studies-of-patients-with-advanced-melanoma-treated-with-the-checkpoint-inhibitor-tremelimumab
#10
Philip Friedlander, Karl Wassmann, Alan M Christenfeld, David Fisher, Chrisann Kyi, John M Kirkwood, Nina Bhardwaj, William K Oh
BACKGROUND: Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to facilitate clinically effective and cost-efficient use of such immunotherapeutic interventions. METHODS: Peripheral blood samples were collected in PAXgene® tubes from 210 treatment-naïve melanoma patients receiving tremelimumab in a worldwide, multicenter phase III study (discovery dataset)...
August 15, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28805361/medicare-program-hospital-inpatient-prospective-payment-systems-for-acute-care-hospitals-and-the-long-term-care-hospital-prospective-payment-system-and-policy-changes-and-fiscal-year-2018-rates-quality-reporting-requirements-for-specific-providers-medicare
#11
(no author information available yet)
We are revising the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals to implement changes arising from our continuing experience with these systems for FY 2018. Some of these changes implement certain statutory provisions contained in the Pathway for Sustainable Growth Rate (SGR) Reform Act of 2013, the Improving Medicare Post-Acute Care Transformation Act of 2014, the Medicare Access and CHIP Reauthorization Act of 2015, the 21st Century Cures Act, and other legislation...
August 14, 2017: Federal Register
https://www.readbyqxmd.com/read/28805135/intermittent-dosing-of-dabrafenib-and-trametinib-in-metastatic-brafv600e-mutated-papillary-thyroid-cancer-two-case-reports
#12
Paul S White, Anita Pudusseri, Stephanie L Lee, Omar Eton
BACKGROUND: A multi-institutional randomized Phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing of these two agents to achieve more durable response, while being better tolerated and more cost effective. PATIENTS: Two consecutive patients with symptomatic, metastatic radioactive iodine (RAI) resistant BRAF V600E mutated papillary thyroid cancer and poor performance status were treated initially with dabrafenib 150mg twice daily plus trametinib 2mg once daily, first in continuous daily dosing, then in a five-week-on and three-week-off schedule...
August 12, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/28804505/an-etiologic-prediction-model-incorporating-biomarkers-to-predict-the-bladder-cancer-risk-associated-with-occupational-exposure-to-aromatic-amines-a-pilot-study
#13
Giuseppe Mastrangelo, Angela Carta, Cecilia Arici, Sofia Pavanello, Stefano Porru
BACKGROUND: No etiological prediction model incorporating biomarkers is available to predict bladder cancer risk associated with occupational exposure to aromatic amines. METHODS: Cases were 199 bladder cancer patients. Clinical, laboratory and genetic data were predictors in logistic regression models (full and short) in which the dependent variable was 1 for 15 patients with aromatic amines related bladder cancer and 0 otherwise. The receiver operating characteristics approach was adopted; the area under the curve was used to evaluate discriminatory ability of models...
2017: Journal of Occupational Medicine and Toxicology
https://www.readbyqxmd.com/read/28803265/measuring-the-end-of-life-premium-in-cancer-using-individual-ex-ante-willingness-to-pay
#14
S Olofsson, U-G Gerdtham, L Hultkrantz, U Persson
For the assessment of value of new therapies in healthcare, Health Technology Assessment (HTA) agencies often review the cost per quality-adjusted life-year (QALY) gained. Some HTA agencies accept a higher cost per QALY gained when treatment is aimed at prolonging survival for patients with a short expected remaining lifetime, a so-called end-of-life (EoL) premium. The objective of this study is to elicit the existence and size of an EoL premium in cancer. Data was collected from 509 individuals in the Swedish general population 20-80 years old using a web-based questionnaire...
August 12, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28803117/phenolics-from-rubus-fairholmianus-induces-cytotoxicity-and-apoptosis-in-human-breast-adenocarcinoma-cells
#15
Blassan P George, Heidi Abrahamse, Nanjundaswamy M Hemmaragala
Herbal medicine is an important part of health care system in most of the countries. Rubus fairholmianus is an unexplored berry in folkloric medicine. In this study, we aimed to understand the importance of R. fairholmianus in pharmaceutical industry for the development of cost-effective cancer therapeutic drugs using in vivo and in vitro analysis. Chemical characterisation, antioxidant, antiproliferative and apoptosis inducing properties of R. fairholmianus root methanolic column subfraction (RFM) were investigated...
August 9, 2017: Chemico-biological Interactions
https://www.readbyqxmd.com/read/28803072/palliative-care-development-in-tajikistan
#16
Nigora Abidjanova
Tajikistan's health system has undergone a series of complex changes associated with reforms aimed at the transition to a more sophisticated control mechanism, financing and operation. As in many developing countries, there is an increase in morbidity and mortality from cancer and chronic diseases, including tuberculosis and HIV. Attention is needed by the state for the development of cost-effective palliative care that will be integrated into the existing public health system. A recent palliative care country needs assessment identified the following areas of work that need to be addressed for palliative care to be implemented: • educating and training of health care professionals, • raising public awareness about palliative care, • making essential palliative care medicines available, • developing the necessary regulatory documents for palliative care development, • developing educational curricula and materials, • integrating palliative care into the medical and nursing universities and schools, • Creating models of palliative care services for home and inpatient facilities...
August 9, 2017: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/28803034/variations-in-the-costs-of-radical-cystectomy-for-bladder-cancer-in-the-usa
#17
Jeffrey J Leow, Alexander P Cole, Thomas Seisen, Joaquim Bellmunt, Matthew Mossanen, Mani Menon, Mark A Preston, Toni K Choueiri, Adam S Kibel, Benjamin I Chung, Maxine Sun, Steven L Chang, Quoc-Dien Trinh
BACKGROUND: Radical cystectomy (RC) for muscle-invasive bladder cancer (BCa) has potential for serious complications, prolonged length of stay and readmissions-all of which may increase costs. Although variations in outcomes are well described, less is known about determinants driving variation in costs. OBJECTIVE: To assess surgeon- and hospital-level variations in costs and predictors of high- and low-cost RC. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of 23 173 patients who underwent RC for BCa in 208 hospitals in the USA from 2003 to 2015 in the Premier Healthcare Database...
August 9, 2017: European Urology
https://www.readbyqxmd.com/read/28802905/thoracic-oncology-clinical-trial-eligibility-criteria-and-requirements-continue-to-increase-in-number-and-complexity
#18
Sandra Garcia, Ajit Bisen, Jingsheng Yan, Xian-Jin Xie, Suresh Ramalingam, Joan H Schiller, David H Johnson, David E Gerber
BACKGROUND: Eligibility criteria and screening procedures are designed to optimize the scientific yield and maximize the safety of clinical trials. However, they may also heighten trial complexity, hinder enrollment, decrease generalizability, and increase costs. We analyzed the types and number of eligibility criteria and screening procedures among thoracic oncology clinical trials sponsored or endorsed by the Eastern Cooperative Oncology Group (ECOG). METHODS: We identified trials and obtained protocols from the ECOG website...
July 24, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28801849/bevacizumab-in-colorectal-cancer-current-role-in-treatment-and-the-potential-of-biosimilars
#19
REVIEW
Lee S Rosen, Ira A Jacobs, Ronald L Burkes
Colorectal cancer (CRC) is a leading cause of tumor-related morbidity and mortality worldwide, with mortality most often attributable to metastatic disease. Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor, has a significant role in the treatment of metastatic CRC (mCRC). However, patient access to bevacizumab may be limited in some regions or circumstances, owing to factors related to insurance coverage, reimbursement, patient out-of-pocket costs, or availability. As a result, outcomes for patients with mCRC may be worsened...
August 11, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28801840/tobacco-related-carcinogenesis-in-head-and-neck-cancer
#20
Ashok R Jethwa, Samir S Khariwala
Head and neck cancer (head and neck squamous cell carcinoma (HNSCC)) is a devastating disease. Patients require intensive treatment that is often disfiguring and debilitating. Those who survive are often left with poor speech articulation, difficulties in chewing and swallowing, and cosmetic disfigurement, as well as loss of taste. Furthermore, given that HNSCC survivors are frequently disabled and unable to return to work, the economic and societal costs associated with HNSCC are massive. HNSCC is one of many cancers that are strongly associated with tobacco use...
August 12, 2017: Cancer Metastasis Reviews
keyword
keyword
100180
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"